Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28302983 | 0.81 | KMT2A (0.48) | KMT2AALDH1A1HTTADORA2AADORA2B | |
| SCHEMBL4058851 | 0.69 | KMT2A (0.33) | KMT2AALDH1A1ADORA2AADORA2B | |
| Iodide SCHEMBL1609671 | 0.68 | KMT2A (0.32) | KMT2AALDH1A1ADORA2AADORA2B | |
| SCHEMBL12473823 | 0.68 | KMT2A (0.32) | KMT2AALDH1A1ADORA2AADORA2B | |
| SCHEMBL24113383 | 0.67 | ADORA2A (0.62) | KMT2AALDH1A1ADORA2AADORA2B | |
| SCHEMBL531646 | 0.67 | KMT2A (0.75) | KMT2AALDH1A1HTTHTR2AMAPT | |
| SCHEMBL5454084 | 0.67 | TSHR (0.67) | KMT2AALDH1A1ADORA2AADORA2BRXFP1 | |
| SCHEMBL27967951 | 0.65 | KMT2A (0.30) | KMT2A | |
| SCHEMBL24113385 | 0.65 | ADORA2A (0.65) | KMT2AALDH1A1ADORA2AADORA2B | |
| SCHEMBL24113514 | 0.65 | ADORA2A (0.67) | ADORA2AADORA2BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148067-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-07-07 | — | — | US | claimed |
| CN-103327816-A | Metal complexes of N-heterocyclic carbenes | UNIV AKRON | 2013-09-25 | — | — | CN | disclosed |
| WO-2013138523-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | WO | disclosed |
| EP-2206439-B1 | Frozen confectionery products comprising theobromine and caffeine | UNILEVER PLC NO 41424 (GB) | 2012-04-18 | — | — | EP | disclosed |
| EP-2206438-B1 | Frozen confectionery and beverage products comprising theobromine and caffeine | UNILEVER PLC NO 41424 (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| WO-2011100671-A2 | METHODS AND COMPOSITIONS TO IMPROVE MECHANICAL RESISTANCE OF TEETH | THEOCORP HOLDING CO., LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110086037-A1 | METHOD OF TREATING INFLAMMATORY DISORDERS | ILIICH EPSHTEIN OLEG | 2011-04-14 | — | — | US | disclosed |
| US-7247721-B2 | Providing a mixture comprising nucleic acids and a charged material comprising any cationic purine; contacting the mixture and a surface to produce a bound material, wherein the bound material comprises nucleic acids covalenty bounded to the surface | LYLES MARK B | 2007-07-24 | — | — | US | disclosed |
| US-20060134301-A1 | Method for making a food composition with a preservative free enhancer and a food composition | UNILEVER BESTFOODS, NORTH AMERICA, DIVISION OF CONOPCO, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-1997011739-A1 | METHOD AND APPARATUS FOR ORAL SPRAY ADMINISTRATION OF CAFFEINE | SPECTOR JOHN E (US) | 1997-04-03 | — | — | WO | disclosed |
| US-4431815-A | CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4425354-A | CARDIOVASCULAR DISORDERS | BURROUGHS WELLCOME CO. (US) | 1984-01-10 | — | — | US | disclosed |
| US-4405634-A | Imidazole derivatives for treating myocardial infarction | BURROUGHS WELLCOME CO. (US) | 1983-09-20 | — | — | US | disclosed |
| US-4396771-A | THROMBOEMBOLIC DISORDERS, SHOCK | BURROUGHS WELLCOME CO. (US) | 1983-08-02 | — | — | US | disclosed |
| US-4357340-A | Imidazole derivatives and angina pectoris | BURROUGHS WELLCOME CO. (US) | 1982-11-02 | — | — | US | disclosed |
| US-4317830-A | ANTISHOCK AGENTS, ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1982-03-02 | — | — | US | disclosed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0000950-A1 | Imidazole derivatives and salts thereof and their synthesis | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |